CORMEDIX INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
CORMEDIX INC. (CRMD) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.95 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.95M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.98M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.15M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.27M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $3.95M 10-K · filed 2026-03-05 |
| 2024-12-31 | $2.98M 10-K · filed 2026-03-05 |
| 2023-12-31 | $6.15M 10-K · filed 2025-03-25 |
| 2022-12-31 | $5.27M 10-K · filed 2024-03-12 |
| 2021-12-31 | $4.43M 10-K · filed 2023-03-30 |
| 2020-12-31 | $3.36M 10-K · filed 2022-03-29 |
| 2019-12-31 | $2.89M 10-K · filed 2021-03-30 |
| 2018-12-31 | $2.45M 10-K · filed 2020-03-16 |
| 2017-12-31 | $2.23M 10-K · filed 2019-05-29 |
| 2016-12-31 | $2.51M 10-K · filed 2018-03-19 |
| 2015-12-31 | $2.35M 10-K · filed 2017-03-16 |
| 2014-12-31 | $1.46M 10-K · filed 2016-03-15 |
| 2013-12-31 | $690.00K 10-K · filed 2015-03-12 |
| 2012-12-31 | $110.00K 10-K · filed 2014-03-31 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |